Holoclara is a biotechnology company developing worm-derived, orally available therapeutics to treat allergic and autoimmune disorders. Its discovery engine mines immunomodulatory molecules from gut roundworms, building on research published in the Proceedings of the National Academy of Sciences. The company uses synthetic chemistry to replicate worm-derived molecules with the aim of producing safe, orally available medicines that could treat or cure prevalent diseases. Holoclara plans to progress its lead therapeutics into the clinic this year while continuing to advance its broader discovery platform to isolate additional therapeutic molecules. The company was founded and is led by physician-scientist Andrea Choe, with co-founders Paul W. Sternberg and Frank C. Schroeder, and is supported by a team of world-renowned worm biology and biotechnology experts and advisors. Holoclara positions itself as the first biotech company focused on creating safe, orally available worm-derived therapies and is backed by leading life sciences and technology investors.

Total raised

$16M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2024